From: A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society
Best fitting model
μ
σ
Disease-free survival
 Capecitabine
Log-normal
6.400
0.908
 Observation
5.437
0.753
Overall survival
6.074
0.627
5.555
0.505